Ms. Jill Annette Strandquist, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 0237 Goldenview Drive, Breckenridge, CO 80424 Phone: 970-547-1288 Fax: 970-547-1289 |
Full Potential, Llc Occupational Therapist - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 579 American Way, Breckenridge, CO 80424 Phone: 970-389-1088 |
Soni Hansen Garrett, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 180 Broken Lance Drive Unit 2, Breckenridge, CO 80424 Phone: 970-485-9523 |
Amy D Perchick, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 137 Gold King Way, Breckenridge, CO 80424 Phone: 215-530-1167 |
Amy D Heflin, OT Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 579 American Way, Breckenridge, CO 80424 Phone: 970-389-1088 |
News Archive
Karolinska Development (publ) have announced the formation of Pergamum AB, a company that will commercialize its dermatology and wound healing opportunities as associated business units within one company. Karolinska Development has transferred all of its holdings from its five dermatology and wound healing companies to Pergamum AB, owning 64% of the new company.
Psychological input into the treatment and management of people with severe asthma can help improve their symptoms, according to a new study.
Flasks, beakers and hot plates may soon be a thing of the past in chemistry labs. Instead of handling a few experiments on a bench top, scientists may simply pop a microchip into a computer and instantly run thousands of chemical reactions, with results - literally shrinking the lab down to the size of a thumbnail.
Surgeons were able to identify and remove a greater number of cancerous nodules from lung cancer patients when combining intraoperative molecular imaging (IMI) – through the use of a contrast agent that makes tumor cells glow during surgery – with preoperative positron emission tomography (PET) scans.
BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.
› Verified 1 days ago